A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to: a) evaluate the tolerability and safety of the
co-administration of Fluzoparib and FOLFIRINOX in patients with resectable pancreatic cancer,
and establish a maximum tolerated dose and recommended phase II dose of the combination and
b) assess the efficacy of the co-administration of Fluzoparib and FOLFIRINOX in patients with
resectable pancreatic cancer.